Athersys, Inc.
United States
Athersys is committed to scientific excellence, helping patients and developing safer and more effective therapies to address unmet medical needs to extend and enhance human life.
286 articles with Athersys, Inc.
-
Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications
8/8/2022
Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS).
-
Athersys Appoints Kasey Rosado as Interim Chief Financial Officer
8/4/2022
Athersys, Inc. announces today its engagement with Ankura Consulting Group, LLC and the appointment of Kasey Rosado as the Company’s interim Chief Financial Officer.
-
Athersys to Host Second Quarter 2022 Financial Results Call
7/26/2022
Athersys, Inc. will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.
-
Athersys and Aspire Capital Fund Terminate Relationship
7/8/2022
Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated.
-
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
-
The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.
-
Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures
6/21/2022
Athersys, Inc. announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET.
-
Athersys Postpones Annual Meeting of Stockholders
6/9/2022
Annual Meeting of Stockholders rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET.
-
Athersys Hosting KOL Panel Event to Discuss TREASURE Data
6/8/2022
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced it will host a panel discussion with leading neurology experts on Tuesday, June 14th at 5:00 p.m. ET.
-
Shares of Cleveland-based Athersys, Inc. are plunging Friday after the company announced a strategic restructuring that will result in the slashing of 70% of its workforce.
-
Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs
6/2/2022
Athersys, Inc. announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
A study conducted by Athersys' partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
-
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study
5/20/2022
Athersys, Inc. announced that its partner, HEALIOS K.K., has reported topline results for its Japan ischemic stroke study, TREASURE.
-
Athersys to Participate in the H.C. Wainwright Global Investment Conference
5/13/2022
Athersys, Inc., announced that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida.
-
Athersys Reports First Quarter 2022 Results
5/6/2022
Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended March 31, 2022.
-
Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference
5/2/2022
Athersys, Inc., announced that Dan Camardo, Chief Executive Officer, and Ivor Macleod, Chief Financial Officer, will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on Wednesday, May 11, 2022 at 4:00 p.m. PT in Las Vegas.
-
Athersys to Announce First Quarter Financial Results on May 6
4/29/2022
Athersys, Inc. (Nasdaq: ATHX) today announced that it will release its first quarter 2022 financial results on Friday, May 6, 2022, at 8:00 a.m. EDT.
-
Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan
4/4/2022
Athersys, Inc. announced that its partner, HEALIOS K.K., has provided updates on its two clinical programs evaluating MultiStem® cell therapy, for which Healios has a license and is responsible for the development and commercialization of MultiStem for ischemic stroke and acute respiratory distress syndrome in Japan on an exclusive basis.
-
Athersys to Participate in Two Upcoming Investor Conferences - Apr 01, 2022
4/1/2022
Athersys, Inc. announced that William Lehmann, President and Chief Operating Officer, will present a corporate overview at the virtual Locust Walk Stem Cell Conference on Monday, April 11, 2022 at 2:00 p.m. ET.